Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,659 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.
Tsai RM, Lobach I, Bang J, Whitwell JL, Senjem ML, Jack CR Jr, Rosen H, Miller B, Boxer AL; AL-108-231 Investigators. Tsai RM, et al. Among authors: bang j. Parkinsonism Relat Disord. 2016 Jul;28:29-35. doi: 10.1016/j.parkreldis.2016.04.006. Epub 2016 Apr 24. Parkinsonism Relat Disord. 2016. PMID: 27132501 Free PMC article. Clinical Trial.
Frontotemporal dementia.
Bang J, Spina S, Miller BL. Bang J, et al. Lancet. 2015 Oct 24;386(10004):1672-82. doi: 10.1016/S0140-6736(15)00461-4. Lancet. 2015. PMID: 26595641 Free PMC article. Review.
Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.
Stamelou M, Schöpe J, Wagenpfeil S, Del Ser T, Bang J, Lobach IY, Luong P, Respondek G, Oertel WH, Boxer A, Höglinger GU; AL-108-231 Investigators, Tauros Investigators, and MDS-Endorsed PSP Study Group. Stamelou M, et al. Among authors: bang j. Mov Disord. 2016 May;31(5):742-7. doi: 10.1002/mds.26580. Epub 2016 Mar 7. Mov Disord. 2016. PMID: 26948290 Free PMC article. Review.
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Dam T, Boxer AL, Golbe LI, Höglinger GU, Morris HR, Litvan I, Lang AE, Corvol JC, Aiba I, Grundman M, Yang L, Tidemann-Miller B, Kupferman J, Harper K, Kamisoglu K, Wald MJ, Graham DL, Gedney L, O'Gorman J, Haeberlein SB; PASSPORT Study Group. Dam T, et al. Nat Med. 2023 Nov;29(11):2955-2956. doi: 10.1038/s41591-022-02076-8. Nat Med. 2023. PMID: 36253611 Free article. No abstract available.
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
Quattrone A, Franzmeier N, Huppertz HJ, Klietz M, Roemer SN, Boxer AL, Levin J, Höglinger GU; AL‐108‐231 Investigators, the Tauros MRI Investigators, the PASSPORT Study Group, the DESCRIBE‐PSP Group. Quattrone A, et al. Mov Disord. 2024 Aug;39(8):1329-1342. doi: 10.1002/mds.29866. Epub 2024 Jun 2. Mov Disord. 2024. PMID: 38825840
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.
Hinkle JT, Perepezko K, Rosenthal LS, Mills KA, Pantelyat A, Mari Z, Tochen L, Bang JY, Gudavalli M, Yoritomo N, Butala A, Bakker CC, Johnson V, Moukheiber E, Dawson TM, Pontone GM. Hinkle JT, et al. Parkinsonism Relat Disord. 2018 Feb;47:50-56. doi: 10.1016/j.parkreldis.2017.11.338. Epub 2017 Nov 21. Parkinsonism Relat Disord. 2018. PMID: 29198499 Free PMC article.
1,659 results